Navigation Links
Cepheid Reports 2009 First Quarter Results

Eighth Quarter of Consecutive Growth in Clinical Reagents; Up 79% From 2008 First Quarter

SUNNYVALE, Calif., April 23 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today reported revenue for the first quarter of 2009 of $38.8 million. Net loss was $7.4 million, or $(0.13) per share, which compares to revenue of $44.8 million and a net loss of $1.9 million, or $(0.03) per share, in the first quarter of fiscal 2008.

Excluding amortization of purchased intangible assets, stock compensation and restructuring expenses, non-GAAP net loss for the first quarter was $2.9 million, or $(0.05) per share. This compares to a non-GAAP net income of $1.7 million, or $0.03 per share, in the first quarter of fiscal 2008.

"Despite broader economic uncertainty, sales for our Clinical tests continued to grow at a significant rate, running over 79% ahead of the first quarter of 2008, and in large part offsetting the anticipated declines in the Partner and Biothreat businesses," said John Bishop, Cepheid's Chief Executive Officer. "Despite the tough sales environment, we placed 95 systems worldwide during the first quarter. Additionally, we achieved an important milestone for Cepheid with the placement of our 1,000th GeneXpert(R) System, highlighting that its ease-of-use and flexibility continue to be compelling."

"Account utilization of our test menu continued to grow during the first quarter, along with our pipeline of available tests," continued Bishop. "We recently released our Xpert(R) MRSA/SA-nasal product in Europe for pre-surgical testing, and expect to release our Xpert(R) TB/RIF for multi-drug resistant tuberculosis in Europe next week. Additionally, I am pleased to announce that we have submitted our Clostridium difficile assay to the FDA for 510(k) market clearance. These product developments further demonstrate that Cepheid is executing well on its vision of providing a broad test menu thereby helping the GeneXpert System to become the molecular testing platform of choice."

Operational Overview

  • Total product sales of $36.6 million compared to $41.9 million in the first quarter of fiscal 2008. By industry, product sales were, in millions:

                                 Three Months Ended
                                      March 31,
                                  2009  2008 Change
                                  ----  ---- ------

    Clinical Systems              $4.8  $7.0    -32%
    Clinical Reagents             19.0  10.6     79%
                                  ----  ----
        Total Clinical            23.8  17.6     35%
    Industrial                     3.7   3.6      3%
    Biothreat                      7.9  12.6    -37%
    Partner                        1.2   8.1    -85%
                                   ---   ---
    Total Product Sales          $36.6 $41.9    -13%

  • By geography, product sales were, in millions:

                                 Three Months Ended
                                      March 31,
                                  2009  2008 Change
                                  ----  ---- ------

    North America
         Clinical                $18.4 $12.8     43%
         Other                    10.8  18.6    -42%
                                  ----  ----
    Total North America           29.2  31.4     -7%

         Clinical                  5.4   4.8     12%
         Other                     2.0   5.7    -65%
                                   ---   ---
    Total International            7.4  10.5    -30%
                                 ----- -----
    Total Product Sales          $36.6 $41.9    -13%
                                 ===== =====

  • During the quarter, Cepheid installed a total of 95 GeneXpert systems and 436 modules. As of March 31, 2009, a cumulative total of 1,042 GeneXpert systems and 5,543 modules have been placed worldwide.
  • GAAP gross margin on product sales was 44% and non-GAAP gross margin on product sales was 46%, which compares to 45% and 47%, respectively, in the first quarter of fiscal 2008.
  • Cash, cash equivalents and investments, net of associated debt, were $36.6 million as of March 31, 2009.
  • DSO improved to 43 days.

Business Outlook

For the fiscal year ending December 31, 2009, the Company expects:

  • Total revenue to be in the range of $164 to $174 million;
  • Net loss in the range of $(0.42) to $(0.47) per share;
  • Non-GAAP net loss in the range of $(0.11) to $(0.17) per share.

Non-GAAP net loss excludes approximately $16 million related to stock compensation expense, $1 million related to the amortization of acquired intangibles, and $0.7 million related to restructuring expenses.

Accessing Cepheid's Q109 Results Conference Call

The Company will host a management presentation at 2:00 p.m. Pacific Time on Thursday, April 23, 2009 to discuss the results. To access the live webcast, please visit Cepheid's website at at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software. A replay of the webcast will be available shortly following the call and will remain available for at least 90 days.

Interested participants and investors may also listen to the live teleconference call by dialing 866-700-6067 (domestic) or 617-213-8834 (international), and entering participant code 21782083. A replay will be available for seven days beginning at about 4:00 p.m. Pacific Time. Access numbers for this replay are 888-286-8010 (domestic) and 617-801-6888 (international), with passcode 78028998.

About Cepheid

Cepheid (Nasdaq: CPHD), based in Sunnyvale, Calif., is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The Company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Cepheid's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the Company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market.

Use of Non-GAAP Measures

The Company has supplemented its reported GAAP financial information with non-GAAP measures that do not include employee share-based compensation expense and amortization of purchased intangible assets and restructuring charges. The presentation of this additional information is not meant to be considered in isolation or as a substitute for results prepared in accordance with GAAP. The Company's management uses the non-GAAP information internally to evaluate its ongoing business, continuing operational performance and cash requirements, and believes these non-GAAP measures are useful to investors as they provide a basis for evaluating the Company's cash requirements and additional insight into the underlying operating results and the Company's ongoing performance in the ordinary course of its operations.

These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. The Company believes that non-GAAP measures have limitations in that they do not reflect all of the amounts associated with its results of operations as determined in accordance with GAAP and that these measures should only be used to evaluate the Company's results of operations in conjunction with the corresponding GAAP measures.

As described above, the Company excludes the following items from one or more of its non-GAAP measures when applicable:

Employee share-based compensation expense. These expenses consist primarily of expenses for employee stock options and employee restricted stock under SFAS 123(R). The Company excludes employee share-based compensation expenses from its non-GAAP measures primarily because they are non-cash expenses that the Company does not believe are reflective of ongoing operating results. Further, as the Company applies SFAS 123(R), it believes that it is useful to investors to understand the impact of the application of SFAS 123(R) on its results of operations.

Amortization of purchased intangible assets. The Company incurs amortization of purchased intangible assets in connection with acquisitions. The Company excludes these items because these expenses are not reflective of ongoing operating results in the period incurred. These amounts arise from the Company's prior acquisitions and have no direct correlation to the operation of the Company's business.

Restructuring expenses. The Company excluded expenses associated with its restructuring from its results for non-GAAP net loss for the first quarter of 2009 and also from its outlook for non-GAAP net loss for fiscal 2009. The Company excluded these items as it believes such amounts are non-recurring in nature, and do not have a direct impact on the operation of the Company's core business.

Forward-Looking Statements

This press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to potential growth in clinical product sales, regulatory developments, product pipeline, demand for certain products, future revenues, future net income and other future operating results. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the Company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: the uncertain impact of the significant global economic downturn on our business, and that of our customers, potential customers and business partners; our success in increasing direct sales and the effectiveness of new sales personnel; the performance and market acceptance of new products; sufficient customer demand; our ability to develop and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the level of testing at clinical customer sites; changes in the protocols or levels of testing for MRSA and other Healthcare Associated Infections (HAIs); the Company's ability to successfully introduce and sell products in clinical markets other than HAIs; the mix of products sold, which can affect gross margins; the rate of environmental biothreat testing conducted by the USPS, which will affect the amount of consumable products sold to the USPS; unforeseen development and manufacturing problems; the potential need for additional intellectual property licenses for tests and other products and the terms of such licenses; lengthy sales cycles in certain markets; the Company's ability to continue to realize manufacturing efficiencies, which are an important factor in improving gross margins; the Company's reliance on distributors in some regions to market, sell and support its products; the occurrence of unforeseen expenditures, acquisitions or other transactions; the impact of acquisitions; the impact of competitive products and pricing; the Company's ability to manage geographically-dispersed operations; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2008 and its other reports filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

    For Media Inquiries:
    Jared Tipton
    Cepheid Corporate Communications
    Tel: (408) 400 8377

    For Investor Inquiries:
    Jacquie Ross
    Cepheid Investor Relations
    Tel: (408) 400 8329

                         FINANCIAL TABLES FOLLOW


                 (in thousands, except per share data)

                                                Three Months Ended
                                                     March 31,
                                                  2009      2008
                                                 ------    ------
      System sales                               $7,909   $14,324
      Reagent and disposable sales               28,679    27,596
                                                 ------    ------
      Total product sales                        36,588    41,920
      Other revenues                              2,179     2,913
                                                  -----     -----
    Total revenues                               38,767    44,833
                                                 ------    ------
    Costs and operating expenses:
      Cost of product sales                      20,511    22,986
      Collaboration profit sharing                2,629     3,733
      Research and development                   10,338     9,898
      Sales and marketing                         6,812     6,941
      General and administrative                  5,269     4,747
      Restructuring charge                          747         -
                                                 ------    ------
        Total costs and operating expenses       46,306    48,305
                                                 ------    ------
    Loss from operations                         (7,539)   (3,472)
    Other income, net                                72     1,282
                                                  -----     -----
    Net loss before income tax benefit           (7,467)   (2,190)
    Income tax benefit                               44       340
                                                  -----    ------
    Net loss                                    $(7,423)  $(1,850)
                                               ========  ========

    Basic and diluted net loss per share         $(0.13)   $(0.03)
                                                =======   =======
    Shares used in computing basic and diluted
     net loss per share                          57,832    56,152
                                                 ======    ======


                                   (in thousands)

                                                           March     December
                                                          31, 2009   31, 2008
                                                          --------   --------
    Current assets:
      Cash and cash equivalents                           $26,808    $23,478
      Restricted cash                                           -      1,500
      Accounts receivable, net                             18,366     18,952
      Inventory                                            35,706     33,498
      Prepaid expenses and other current assets             3,209      4,636
                                                            -----      -----
    Total current assets                                   84,089     82,064
    Property and equipment, net                            23,297     24,109
    Investments                                            24,431     24,539
    Other non-current assets                                  934        920
    Intangible assets                                      39,266     36,932
    Goodwill                                               18,626     18,556
                                                           ------     ------
    Total assets                                         $190,643   $187,120
                                                         ========   ========

    Current liabilities:
      Accounts payable                                    $15,081     $9,669
      Accrued compensation                                  5,923      7,919
      Accrued royalties                                     7,860      5,953
      Accrued collaboration profit sharing                    870      2,023
      Accrued other liabilities                             7,722      6,816
      Current portion of deferred revenue                   2,214      2,834
      Bank borrowing                                       14,598     14,639
                                                           ------     ------
    Total current liabilities                              54,268     49,853
    Long-term portion of deferred revenue                   1,810      1,753
    Other liabilities                                       4,820      3,549
                                                            -----      -----
    Total liabilities                                      60,898     55,155
                                                           ------     ------
    Shareholders' equity:
      Common stock                                        268,541    266,991
      Additional paid-in capital                           45,230     41,619
      Accumulated other comprehensive income (loss)            19        (23)
      Accumulated deficit                                (184,045)  (176,622)
                                                        ---------  ---------
    Total shareholders' equity                            129,745    131,965
                                                          -------    -------
    Total liabilities and shareholders' equity           $190,643   $187,120
                                                         ========   ========


                                 (in thousands)
                                                           Three Months Ended
                                                               March 31,
                                                            2009       2008
                                                           ------     ------
    Cash flows from operating activities:
      Net loss                                            $(7,423)   $(1,850)
      Adjustments to reconcile net loss to net cash
       provided by (used in) operating activities:
      Depreciation and amortization                         2,090      1,941
      Amortization of intangible assets                     1,516      1,155
      Amortization of prepaid compensation expense             63         63
      Stock-based compensation related to employees and
       consulting services rendered                         3,547      3,261
      Unrealized gain on auction rate securities           (2,971)         -
      Unrealized loss on put option                         3,079          -
      Deferred rent                                           (74)       (31)
      Changes in operating assets and liabilities:
        Accounts receivable                                   587     (5,278)
        Inventory                                          (2,139)    (3,237)
        Prepaid expenses and other current assets           1,358     (1,261)
        Other non-current assets                              (15)      (143)
        Accounts payable and other current liabilities      6,119      6,802
        Accrued compensation                               (1,996)    (2,730)
        Deferred revenue                                     (563)      (346)
                                                            -----      -----
          Net cash provided by (used in) operating
           activities                                       3,178     (1,654)
                                                            -----    -------

    Cash flows from investing activities:
      Capital expenditures                                 (1,420)    (4,674)
      Payments for technology licenses                     (1,500)         -
      Cost of acquisition, net of cash acquired              (148)         -
      Proceeds from maturities of marketable securities         -      2,550
      Proceeds from the sale of fixed assets                    8         24
      Transfer to unrestricted cash                         1,500        517
                                                            -----      -----
        Net cash used in investing activities              (1,560)    (1,583)
                                                          -------    -------

    Cash flows from financing activities:
      Net proceeds from the issuance of common shares and
       exercise of stock options and awards                 1,551      6,732
      Principal payments of bank borrowing                    (41)         -
      Principal payments of notes payable                       -         (4)
                                                            -----      -----
        Net cash provided by financing activities           1,510      6,728
                                                            -----      -----

    Effect of exchange rate change on cash                    202         33
                                                            -----      -----
    Net increase in cash and cash equivalents               3,330      3,524
    Cash and cash equivalents at beginning of period       23,478     16,476
                                                           ------     ------
    Cash and cash equivalents at end of period            $26,808    $20,000
                                                          =======    =======


                        (in thousands, except per share data)

                                                        Three Months Ended
                                                             March 31,
                                                           2009    2008
                                                          ------   ------

    Total product sales                                  $36,588  $41,920
    Total revenues                                       $38,767  $44,833

    Cost of product sales                                $20,511  $22,986
      Stock compensation expense                            (354)    (350)
      Amortization of purchased intangible assets           (324)    (241)
                                                          ------   ------
    Non-GAAP measure of cost of product sales            $19,833  $22,395

    Gross margin on product sales per GAAP                    44%      45%
    Gross margin on product sales per non-GAAP                46%      47%

    Research and development                             $10,338   $9,898
      Amortization of purchased intangible assets            (24)     (24)
      Stock compensation expense                          (1,305)  (1,263)
                                                          ------   ------
    Non-GAAP measure of cost of research and
     development                                          $9,009   $8,611

    Sales and marketing                                   $6,812   $6,941
      Amortization of purchased intangible assets            (49)     (21)
      Stock compensation expense                            (710)    (845)
                                                          ------   ------
    Non-GAAP measure of cost of sales and marketing       $6,053   $6,075

    General and administrative                            $5,269   $4,747
      Stock compensation expense                          (1,053)    (803)
                                                          ------   ------
    Non-GAAP measure of cost of general and
     administrative                                       $4,216   $3,944

    Income (loss) from operations                        $(7,539) $(3,472)
      Restructuring charge                                   747        -
      Stock compensation expense                           3,422    3,261
      Amortization of purchased intangible assets            397      286
                                                          ------   ------
    Non-GAAP measure of income (loss) from
     operations                                          $(2,973)     $75

    Net income (loss)                                    $(7,423) $(1,850)
      Restructuring charge                                   747        -
      Stock compensation expense                           3,422    3,261
      Amortization of purchased intangible assets            397      286
                                                          ------   ------
    Non-GAAP measure of net income (loss)                $(2,857)  $1,697

    Basic and diluted net income (loss) per share         $(0.13)  $(0.03)
      Restructuring charge                                  0.01        -
      Stock compensation expense                            0.06     0.05
      Amortization of purchased intangible assets           0.01     0.01
                                                          ------   ------
    Non-GAAP measure of net income (loss)                 $(0.05)   $0.03

    Shares used in computing basic and diluted net
     income (loss) per share                              57,832   56,152
      Incremental shares from the assumed conversion
       of dilutive stock options                               -    5,868
                                                          ------   ------
    Shares used in computing diluted net income
     (loss) per share                                     57,832   62,020

SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
2. Cepheid to Present at Thomas Weisel Partners Healthcare Conference
3. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
4. Cepheid to Present at William Blair Small-Cap Growth Stock Conference
5. Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference
6. Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System
7. Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results
8. Cepheid Appoints Senior VP, Chief Financial Officer to Management Team
9. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
10. Cepheid Reports Fourth Quarter and Full Year 2007 Results
11. Cepheid to Present at Cowen and Companys 28th Annual Healthcare Conference
Post Your Comments:
(Date:11/24/2015)... ... 24, 2015 , ... This fall, global software solutions leader SAP and AdVenture ... develop and pitch their BIG ideas to improve health and wellness in their schools. ... to win the title of SAP's Teen Innovator, an all-expenses paid trip to Super ...
(Date:11/24/2015)... 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its ... at 11:00 a.m. Israel time, at the law ... Allon Street, 36 th Floor, Tel Aviv, Israel ... and Izhak Tamir to the Board of Directors; ... directors; , approval of an amendment to certain terms of options ...
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier of ... has promoted Melanie Aregger to serve as Chief Operating Officer. , Having ... management team and was promoted to Head of InSphero Diagnostics in 2014. ...
(Date:11/24/2015)... , Nov. 24, 2015 HemoShear ... on discovering drugs for metabolic disorders, announced today ... to its Board of Directors (BOD). Mr. Watkins ... of Human Genome Sciences (HGS), and also served ... Jim Powers , Chairman and CEO ...
Breaking Biology Technology:
(Date:11/9/2015)... JOSE, Calif. , Nov. 9, 2015  Synaptics ... human interface solutions, today announced broader entry into the ... vehicle-specific solutions that match the pace of consumer electronics ... and biometric sensors are ideal for the automotive industry ... vehicle. Europe , ...
(Date:10/29/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that it has been selected ... of only three finalists for a 2015 Tekne ... category. The Tekne Awards honor Minnesota ... and leadership. iMedNet™ eClinical  technology ...
(Date:10/29/2015)... Mich. , Oct. 29, 2015  Rubicon ... Genomics for U.S. distribution of its DNA library ... kit and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX ... enable the preparation of NGS libraries for liquid ... for diagnostic and prognostic applications in cancer and ...
Breaking Biology News(10 mins):